Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus Taxane/Carboplatin in First-Line Advanced NSCLC
NCT00112294Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2004
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Dec 2004; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00112294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112294.